1. Report Overview

1.1 World IBD Drugs Market: Overview of Findings

1.2 Why You Should Read This Report

1.3 How the Study Delivers

1.4 Main Questions Covered in the Analysis

1.5 Who Is This Report For?

1.6 Methods of Research and Analysis

1.7 Frequently Asked Questions (FAQ)

1.8 Associated Reports

1.9 About Visiongain

2. Introduction to the Inflammatory Bowel Disease Drug Market

2.1 What is Inflammatory Bowel Disease (IBD)?

2.2 Classification of IBD

2.3 Symptoms and Diagnosis of IBD

2.4 Multifactorial Causes of IBD

2.5 How Common is IBD?

2.6 What Are the Treatment Options for IBD?

2.6.1 Aminosalicylates – The Most Common therapy

2.6.2 Antibiotics – Will There Be Any Supporting Evidence Soon?

2.6.3 Corticosteroids – Uptake from Uceris?

2.6.4 Immunomodulators – Slow to Act?

2.6.5 Monoclonal Antibodies – Not cost-effective?

2.7 Treatment Goals for IBD – Treat-to-Target Approach?

2.8 Treatment Algorithm – is Top-Down Approach the Future Direction?

3. The World Inflammatory Bowel Disease Drug Market, 2017-2027

3.1 The Inflammatory Bowel Disease Market in 2016 and 2017

3.2 Forecast 2017-2027: Impacted by Biosimilars?

3.3 Biologic Therapies Forecast 2017-2027 – Driving the Market

3.4 Aminosalicylates Forecast 2017-2027: The Work Horse of IBD Market

3.5 Antibiotics Forecast 2017-2027: Growing Despite Challenges

3.6 Corticosteroids Forecast 2017-2027: Driven by Uceris

3.7 Immunomodulators Forecast 2017-2027 – Will Slowly Lose Market Share

4. Market Prospects for Leading IBD Drugs, 2017-2027

4.1 Humira (AbbVie) – Growing in the First Half of Forecast Period

4.1.1 Humira: Forecast and Analysis, 2017-2027

4.2 Remicade (Janssen Biotech) – Will Slowly be Eroded by Biosimilars

4.2.1 Remicade: Forecast and Analysis, 2017-2027

4.3 Asacol (Allergan) – Threat from Generic Competition

4.3.1 Asacol: Forecast and Analysis, 2017-2027

4.4 Pentasa (Shire) – Differentiated by Its Delivery System

4.4.1 Pentasa: Forecast and Analysis, 2017-2027

4.5 Lialda (Shire) – Will Improved Compliance Increase Revenue?

4.5.1 Lialda: Forecast and Analysis, 2017-2027

4.6 Tysabri (Perrigo) – Still Protected by Patent

4.6.1 Tysabri: Forecast and Analysis, 2017-2027

4.7 Xifaxan (Valeant) – Still Growing Significantly

4.7.1 Xifaxan: Forecast and Analysis, 2017-2027

4.8 Cimzia (UCB) – How Will It Fare Against Biosimilars?

4.8.1 Cimzia: Forecast and Analysis, 2017-2027

4.9 Entocort (AstraZeneca) – A Slow and Steady Decline?

4.9.1 Entocort: Forecast and Analysis, 2017-2027

4.10 Neoral (Novartis) – Will its Side Effect Profile Hamper Sales Growth?

4.10.1 Neoral: Forecast and Analysis, 2017-2027

4.11 Medrol (Pfizer) – Another Leading Steroid

4.11.1 Medrol: Forecast and Analysis, 2017-2027

4.12 Canasa (Allergan) – Will a Generic Competitor Soon Be Available?

4.12.1 Canasa/Salofalk: Forecast and Analysis, 2017-2027

4.13 Apriso (Valeant) – Challenger to Asacol?

4.13.1 Apriso: Forecast and Analysis, 2017-2027

4.14 Azulfidine (Pfizer) – Tried, Tested and Staying in the Market

4.14.1 Azulfidine: Forecast and Analysis, 2017-2027

4.15 Entyvio (Takeda Pharmaceuticals) – Driving the Biologics Segment

4.15.1 Entyvio: Forecast and Analysis, 2017-2027

4.16 Simponi (Janssen Biotech) – Rising Star for the Market?

4.16.1 Simponi: Forecast and Analysis, 2017-2027

4.17 Uceris (Valeant) – Meeting Patients’ Needs with Its Delivery System

4.17.1 Uceris: Forecast and Analysis, 2017-2027

5. Leading National Markets: Sales Outlooks, 2017-2027

5.1 IBD Drugs - Leading National Markets 2016

5.2 The US IBD Drug Market, 2017-2017 – The World Leader

5.3 The Japanese IBD Drug Market, 2017-2027 – Growing Significantly?

5.4 The EU-5 IBD Drug Market, 2017-2027 – Driven by the UK

5.4.1 The German IBD Drug Market, 2017-2027

5.4.2 The French IBD Drug Market, 2017-2027

5.4.3 The UK IBD Drug Market, 2017-2027

5.4.4 The Spanish IBD Drug Market, 2017-2027

5.4.5 The Italian IBD Drug Market, 2017-2027

5.5 IBD Drug Markets in BRIC Countries – Taking More Market Share

5.5.1 The Brazilian IBD Drug Market, 2017-2027

5.5.2 The Russian IBD Drug Market, 2017-2027

5.5.3 The Indian Drug Market, 2017-2027

5.5.4 The Chinese IBD Drug Market, 2017-2027

6. The R&D Pipeline for Inflammatory Bowel Disease, 2016

6.1 Top Marketed and pipeline products – Launch dates and Patent expiry

6.2 Interleukin (IL) Inhibitors – One of the Main Areas of Innovation

6.2.1 CyCol (Sigmoid Pharma)

6.2.2 PF-04236921 (Pfizer)

6.2.3 QAX 576 (Novartis)

6.2.4 TNF Kinoid (Neovacs)

6.2.5 Vidofludimus (4SC) – Suspended

6.2.6 Stelara (Ustekinumab, CNTO 1275, Janssen Biotech)

6.3 Cell-Adhesion Molecule (CAM) Inhibitors – A Promising Avenue

6.3.1 AJG 511 (Ajinomoto Pharmaceutical Co.)

6.3.2 AJM 300 (Ajinomoto Pharmaceuticals)

6.3.3 MEDI 7183/AMG 181 (AstraZeneca)

6.3.4 Etrolizumab (Roche)

6.3.5 PF-00547659 (Pfizer)

6.3.6 Alicaforsen (ISIS 2302, Atlantic Healthcare)

6.4 TNF-α Inhibitors – a Specific Target

6.4.1 AVX-470 (Avaxia Biologics)

6.4.2 Ozoralizumab (ALX-0061, Ablynx)

6.5 Stem Cell Therapies – Basis for a Cure?

6.5.1 Ovasave (TxCell)

6.5.2 MultiStem (Athersys and Pfizer)

6.5.3 Prochymal (Remestemcel-L, Osiris Therapeutics)

6.5.4 Cx601 (TiGenix)

6.6 JAK Inhibitors – New Target Pathway

6.6.1 JNJ-54781532 (Janssen)

6.6.2 Xeljanz, (Tofacitinib, CP-690550, Pfizer)

6.7 Toll-like Receptor Agonists

6.7.1 BL-7040 (BioLineRX)

6.7.2 Kappaproct (InDex Pharmaceuticals)

6.8 Other Classes of Agent

6.8.1 Trichuris suis ova (CNDO-201, Coronado Biosciences)

6.8.2 GLPG0974 (Galapagos)

6.8.3 RPC1063 (Receptos/now Celgene)

6.8.4 SGX203 (Soligenix)

6.8.5 Mongersen (GED-0301, Celgene)

6.8.6 Tetomilast (OPC-6535, Otsuka)

6.8.7 Laquinimod (Active Biotech)

6.8.8 RHB-104 (RedHill Biopharma)

6.8.9 Ozanimod (Celgene)

6.8.10 GED-0301 (Celgene)

6.9 Biosimilar Candidates – Promising Competitors of Leading Biologics

6.9.1 Adalimumab Biosimilars

6.9.2 Infliximab Biosimilars

7. Drivers and Restraints in the Inflammatory Bowel Disease Drug Industry and Market, 2016

7.1 SWOT and STEP Analyses of the IBD Drugs Market

7.2 What Factors Will Stimulate the IBD Market?

7.2.1 Increasing Disease Incidence in Most National Markets

7.2.2 Better Diagnosis – Early Referrals

7.2.3 Delivery Systems Improve Existing Drugs

7.2.4 Biological Drugs – Driving the Market Significantly

7.2.5 Socioeconomic Costs of IBD

7.3 What Factors Will Restrain the Market?

7.3.1 Lack of Understanding of Disease Aetiology

7.3.2 Compliance – Frequent Dosing is Inconvenient

7.3.3 Limitations of Biologics – Side Effect Profiles

7.3.4 The Possible Development of Alternative Treatments

7.3.5 Surgery – Treatment for Recalcitrant IBD

7.3.6 Health Care Cost Containment

8. Leading Companies in the IBD Pharmaceuticals Market, 2016

8.1 The Largest Companies by Revenue

8.1.1 AbbVie

8.1.2 Janssen Biotech

8.1.3 Allergan

8.1.4 Shire Pharmaceuticals

9. Conclusions of the Study

9.1 The IBD Drugs Market Will Expand from 2017 to 2027

9.2 Aminosalicylates and Other Non-Biologic Treatments

9.3 Biological Treatments Dominate the Market

9.4 Improvements Needed in IBD Therapy

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 2.1 Differentiating Crohn’s Disease and Ulcerative Colitis

Table 2.2 Worldwide Prevalence Rates for IBD, 2016

Table 2.3 Worldwide Incidence Rates for IBD, 2016

Table 2.4 Geographical Variations in the Incidence of IBD, 2016

Table 2.5 Other Drug Types Used to Treat IBD, 2016

Table 2.6 Treatment Protocol for IBD, 2016

Table 3.1 Global IBD Drug Sales ($m), Annual Growth Rates (%) and Market Shares (%) by Segment, 2016 and 2017

Table 3.2 Global IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 3.3 Global IBD Drug Forecast by Drug Category: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 3.4 Global IBD Drug Market Drivers and Restraints 2017-2027

Table 3.5 Global Biologics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 3.6 Global Biologic Therapies Drivers and Restraints, 2017-2027

Table 3.7 Global Aminosalicylates Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 3.8 Global Aminosalicylates Drivers and Restraints, 2017-2027

Table 3.9 Global Antibiotics Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 3.10 Global Antibiotics Drivers and Restraints, 2017-2027

Table 3.11 Global Corticosteroids Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 3.12 Global Corticosteroids Drivers and Restraints, 2017-2027

Table 3.13 Global Immunomodulators Forecast for IBD Market: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 3.14 Global Immunomodulators Drivers and Restraints, 2017-2027

Table 4.1 Leading IBD Treatments by Revenue ($m), 2016

Table 4.2 Leading IBD Medicines: Revenue Forecasts ($m), AGR (%), 2016-2027

Table 4.3 World Humira Revenue Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.4 Drivers and Restraints for Humira, 2017-2027

Table 4.5 World Remicade Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.6 Drivers and Restraints for Remicade, 2017-2027

Table 4.7 World Asacol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.8 Drivers and Restraints for Asacol, 2017-2027

Table 4.9 World Pentasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.10 Drivers and Restraints for Pentasa, 2017-2027

Table 4.11 World Lialda Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.12 Drivers and Restraints for Lialda, 2017-2027

Table 4.13 World Tysabri Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.14 Drivers and Restraints for Tysabri, 2017-2027

Table 4.15 World Xifaxan Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.16 Drivers and Restraints for Xifaxan, 2017-2027

Table 4.17 World Cimzia Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.18 Drivers and Restraints for Cimzia, 2017-2027

Table 4.19 World Entocort Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.20 Drivers and Restraints for Entocort, 2017-2027

Table 4.21 World Neoral Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.22 Drivers and Restraints for Neoral, 2017-2027

Table 4.23 World Medrol Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.24 Drivers and Restraints for Medrol, 2017-2027

Table 4.25 World Canasa Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.26 Drivers and Restraints for Canasa, 2017-2027

Table 4.27 World Apriso Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.28 Drivers and Restraints for Apriso, 2017-2027

Table 4.29 World Azulfidine Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.30 Drivers and Restraints for Azulfidine, 2017-2027

Table 4.31 World Entyvio Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.32 Drivers and Restraints for Entyvio, 2017-2027

Table 4.33 World Simponi Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.34 Drivers and Restraints for Simponi, 2017-2027

Table 4.35 World Uceris Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 4.36 Drivers and Restraints for Uceris, 2017-2027

Table 5.1 IBD Drug Revenues ($m) by Leading Country, 2016

Table 5.2 US IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.3 Japanese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.4 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2021

Table 5.5 EU5 IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2021-2027

Table 5.6 German IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.7 French IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.8 UK IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.9 Spanish IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.10 Italian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.11 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2016-2021

Table 5.12 BRIC IBD Drug Market Forecasts: Revenues ($m), AGR (%), CAGR (%), 2021-2027

Table 5.13 Brazilian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.14 Russian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.15 Indian IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 5.16 Chinese IBD Drug Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027

Table 6.1 Key Patent dates for marketed and pipeline products

Table 6.2 Selected IL Inhibitors in Clinical Development, 2016

Table 6.3 Selected CAM Inhibitors in Clinical Development, 2016

Table 6.4 Selected TNF-α Inhibitors in Clinical Development, 2016

Table 6.5 Selected Stem Cell Therapies in Clinical Development, 2016

Table 6.6 Selected JAK Inhibitors in Clinical Development, 2016

Table 6.7 Selected Toll-like Receptor Agonist in Clinical Development, 2016

Table 6.8 Selected Other Classes in Clinical Development, 2016

Table 7.1 Strengths, Weaknesses, Opportunities and Threats in the IBD Drug Market, 2016

Table 7.2 Social, Technological, Economic and Political Forces on the IBD Drug Market, 2016

Table 8.1 Top 4 Companies for IBD Drugs: Revenues ($m) and Market Shares (%), 2016

Table 8.2 AbbVie Revenues ($m) and Market Share (%), 2016

Table 8.3 Janssen Biotech Revenues ($m) and Market Share (%), 2016

Table 8.4 Allergan Revenues ($m) and Market Share (%), 2016

Table 8.5 Shire Revenues ($m) and Market Share (%), 2016

Table 9.1 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Share (%) by Product Category, 2016, 2021, 2027

Table 9.2 Global IBD Revenue Forecasts ($m), CAGR (%) and Market Shares (%) by Region, 2016, 2021, 2027

List of Figures

Figure 1.1 Inflammatory Bowel Disease Market Segmentation, 2016

Figure 3.1 World IBD Drugs Market Shares by Product Type (%), 2016

Figure 3.2 Global IBD Drug Market Forecast ($m), 2016-2027

Figure 3.3 World IBD Drugs Market Shares by Product Type (%), 2027

Figure 3.4 Global Biologics Forecast for IBD Market ($m), 2016-2027

Figure 3.5 Global Aminosalicylates Forecast for IBD Market ($m), 2016-2027

Figure 3.6 Global Antibiotics Forecast for IBD Market ($m), 2016-2027

Figure 3.7 Global Corticosteroids Forecast for IBD Market ($m), 2016-2027

Figure 3.8 Global Immunomodulators Forecast for IBD Market ($m), 2016-2027

Figure 4.1 World Humira Revenue Forecast ($m), 2016-2027

Figure 4.2 World Remicade Forecast ($m), 2016-2027

Figure 4.3 World Asacol Forecast ($m), 2016-2027

Figure 4.4 World Pentasa Forecast ($m), 2016-2027

Figure 4.5 World Lialda Forecast ($m), 2016-2027

Figure 4.6 World Tysabri Forecast ($m), 2016-2027

Figure 4.7 World Xifaxan Forecast ($m), 2016-2027

Figure 4.8 World Cimzia Forecast ($m), 2016-2027

Figure 4.9 World Entocort Forecast ($m), 2016-2027

Figure 4.10 World Neoral Forecast ($m), 2016-2027

Figure 4.11 World Medrol Forecast ($m), 2016-2027

Figure 4.12 World Canasa Forecast ($m), 2016-2027

Figure 4.13 World Apriso Forecast ($m), 2016-2027

Figure 4.14 World Azulfidine Forecast ($m), 2016-2027

Figure 4.15 World Entyvio Forecast ($m), 2016-2027

Figure 4.16 World Simponi Forecast ($m), 2016-2027

Figure 4.17 World Uceris Forecast ($m), 2016-2027

Figure 5.1 Global IBD Drug Market by Leading Country (%), 2016

Figure 5.2 Global IBD Drug Market by Leading Country (%), 2027

Figure 5.3 US IBD Drug Market Forecast ($m), 2016-2027

Figure 5.4 Japanese IBD Drug Market Forecast ($m), 2016-2027

Figure 5.5 EU5 IBD Drug Market Forecasts ($m), 2016-2027

Figure 5.6 German IBD Drug Market Forecast ($m), 2016-2027

Figure 5.7 French IBD Drug Market Forecast ($m), 2016-2027

Figure 5.8 UK IBD Drug Market Forecast ($m), 2016-2027

Figure 5.9 Spanish IBD Drug Market Forecast ($m), 2016-2027

Figure 5.10 Italian IBD Drug Market Forecast ($m), 2016-2027

Figure 5.11 BRIC IBD Drug Market Forecasts ($m), 2016-2027

Figure 5.12 Brazilian IBD Drug Market Forecast ($m), 2016-2027

Figure 5.13 Russian IBD Drug Market Forecast ($m), 2016-2027

Figure 5.14 Indian IBD Drug Market Forecast ($m), 2016-2027

Figure 5.15 Chinese IBD Drug Market Forecast ($m), 2016-2027

Figure 8.1 Top Producers of IBD Drugs: Market Shares (%), 2016

Figure 8.2 AbbVie Assets – Marketed and Pipeline 2016

Figure 8.3 AbbVie Deals and Partnerships 2011 - 2016

Figure 8.4 Janssen Assets – Marketed and Pipeline 2016

Figure 8.5 Janssen – Deals and Partnerships 2011 - 2016

Figure 8.6 Allergan Assets – Marketed and Pipeline 2016

Figure 8.7 Allergan – Deals and Partnerships 2011 - 2016

Figure 8.8 Shire Assets – Marketed and Pipeline 2016

Figure 8.9 Shire – Deals and Partnerships 2011 - 2016